Publication:
Nonconvulsive status epilepticus cases arising in connection with cephalosporins

dc.contributor.authorBora, İbrahim
dc.contributor.authorDemir, Aylin Bican
dc.contributor.authorUzun, Pınar
dc.contributor.buuauthorBORA, İBRAHİM HAKKI
dc.contributor.buuauthorBİCAN DEMİR, AYLİN
dc.contributor.buuauthorUzun, Pınar
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentNöroloji Ana Bilim Dalı
dc.contributor.orcid0000-0001-6739-8605
dc.contributor.researcheridENI-7759-2022
dc.contributor.researcheridKHB-9765-2024
dc.contributor.researcheridGIK-0439-2022
dc.date.accessioned2024-09-26T12:03:43Z
dc.date.available2024-09-26T12:03:43Z
dc.date.issued2016-01-01
dc.description.abstractCephalosporins, particularly cefepime, exert neurotoxic side effects that can lead to status epilepticus. These neurotoxic side effects include myoclonus, dystonic movements, tremor, asterixis, seizure, status epilepticus, encephalopathy, and sometimes coma. Status epilepticus, particularly nonconvulsive status epilepticus (NCSE), is a well-known but unusual complication in patients with altered renal function who were receiving treatment with intravenous cephalosporins, especially cefepime. We reviewed the clinical and electroencephalographic (EEG) characteristics of 7 patients with renal failure who developed consciousness alterations with changes in EEG activity while being treated with cephalosporins. All patients developed renal failure: six patients had chronic renal failure, one patient had acute renal failure, and two patients were administered hemodialysis. Nonconvulsive status epilepticus was observed between 2 and 8 days (average of 5.6 days) after initiation of cephalosporins. Cephalosporins are epileptogenic drugs, especially when used in excessive doses or when renal function is impaired. Critically ill patients with chronic kidney disease are particularly susceptible to cefepime neurotoxicity. Clinical and electrophysiological results of patients guide the diagnosis of NCSE by healthcare providers. (C) 2016 Published by Elsevier Inc.
dc.identifier.doi10.1016/j.ebcr.2016.04.005
dc.identifier.endpage27
dc.identifier.issn2213-3232
dc.identifier.scopus2-s2.0-84975450164
dc.identifier.startpage23
dc.identifier.urihttps://doi.org/10.1016/j.ebcr.2016.04.005
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2213323216300196?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11452/45326
dc.identifier.volume6
dc.identifier.wos000395317200007
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.journalEpilepsy & Behavior Case Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPharmacokinetic considerations
dc.subjectEncephalopathy
dc.subjectNeurotoxicity
dc.subjectNonconvulsive status epilepticus
dc.subjectCephalosporin
dc.subjectPrognosis
dc.subjectTreatment
dc.subjectNeurosciences & neurology
dc.titleNonconvulsive status epilepticus cases arising in connection with cephalosporins
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Nöroloji Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication7674bbf4-9c63-42a4-b1e0-09ecdcb8f05a
relation.isAuthorOfPublication8b72317c-2cda-4511-bba9-51f797dadec4
relation.isAuthorOfPublication.latestForDiscovery7674bbf4-9c63-42a4-b1e0-09ecdcb8f05a

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bora_vd_2016.pdf
Size:
949.82 KB
Format:
Adobe Portable Document Format